Click here to view the programme of Session 5a

Chairs:
Hanneke van Laarhoven, medcial oncologist, Amsterdam UMC, Amsterdam, the Netherlands
Daisuke Takahari, medical oncologist, Cancer Institute Hospital of JFCR, Tokyo, Japan

10:45 Tissue biomarkers to direct treatment
Elizabeth Smyth, medical oncologist, Cambridge University Hospital Cambridge, United Kingdom

11:05 Promising targets and new agents in early drug development
Sun Rha, medical oncologist, Yonsei University, Korea

11:25 The role of ctDNA
Marieke Vollebergh, medical oncologist, NKI, Amsterdam, The Netherlands

11:45 Accepted oral abstract 03.3.4: Molecular biological analysis of novel multidrug resistance-related gene by using gastric cancer organoids
Naoya Sakamoto, Pathologist, Division of Pathology, EPOC, National Cancer Center, Japan

11:55 Accepted oral abstract 03.3.5: Tislelizumab Combined with Anlotinib and XELOX as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (TALENT)
Ling Ma, Gastroenterologist, The First Affiliated Hospital of Nanjing Medical University,  China

12:05 Accepted oral abstract 03.3.6: Efficacy of Preoperative Chemotherapy with Modified Dose DCS Regimen for Bulky Lymph Nodes Gastric Cancer
Vo Duy Long, Surgeon, University Medical Center at Ho Chi Minh city, Vietnam 

12:15 End of session

  • Parallel session 1

    Session 5a: Medical Oncology – Novel drugs and technologies

    Date: 10 May 2025Time: 10:45 - 12:15 CET